Back
Align Technology 10K Form
Buy
56
ALGN
Align Technology
Last Price:
304.94
Seasonality Move:
0.26%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2021-02-26 | 10K | ALGN/Align Technology Annual |
2020-07-31 | 10Q | ALGN/Align Technology Quarterly |
2020-05-05 | 10Q | ALGN/Align Technology Quarterly |
2020-02-28 | 10K | ALGN/Align Technology Annual |
2019-10-31 | 10Q | ALGN/Align Technology Quarterly |
2019-08-01 | 10Q | ALGN/Align Technology Quarterly |
Receive ALGN News And Ratings
See the #1 stock for the next 7 days that we like better than ALGN
ALGN Financial Statistics
Sales & Book Value
Annual Sales: | $3.73B |
---|---|
Cash Flow: | $135.78M |
Price / Cash Flow: | 50.64 |
Annual Sales: | $45.48 |
Price / Book: | 6.71 |
Profitability
EPS (TTM): | 4.05000 |
---|---|
Net Income (TTM): | $315.07M |
Gross Margin: | $2.63B |
Return on Equity: | 8.73% |
Return on Assets: | 5.34% |
Align Technology Earnings Forecast
Key Align Technology Financial Ratios
- The Gross Profit Margin over the past 24 years for ALGN is 70.52%.
- The Selling, General & Administrative Expenses for ALGN have been equal to 44.84% of Gross Profit Margin.
- The Research & Development expenses have been 8.17% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of ALGN is 9.68% of Total Revenues.
- Per Share Earnings over the last 24 years have been positive in 14 years.
Align Technology Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Medical Devices |
Sector: | Healthcare |
Current Symbol: | ALGN |
CUSIP: | 016255 |
Website: | aligntech.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 1.16 |
Quick Ratio: | 0.95 |
Price-to-Earnings
Trailing P/E Ratio: | 66.19 |
---|---|
Forward P/E Ratio: | 30.69 |
ALGN Technical Analysis vs Fundamental Analysis
Buy
56
Align Technology (ALGN)
is a Buy
Is Align Technology a Buy or a Sell?
-
Align Technology stock is rated a Buy
The current Align Technology [ALGN] share price is $305.15. The Score for ALGN is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.